Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Moody's Affirms Mylan (MYL) at 'Baa3'; Moves Outlook to Developing (TEVA)
April 22, 2015 10:03 AM EDTMoody's Investors Service affirmed the Baa3 senior unsecured rating of Mylan Inc. (subsidiary of Mylan NV, together Mylan (Nasdaq: MYL)) and changed the outlook to developing from stable. The change in outlook reflects heightened event risk and uncertainty around the direction of the ratings given Teva Pharmaceutical Industries Ltd's (Teva, A3 negative, (NYSE: TEVA)) unsolicited offer to acquire Mylan. Teva's offer follows Mylan's unsolicited offer to acquire Perrigo Company plc (Baa3 stable), which Perrigo... More
Teva Pharma (TEVA) Files HSR Notification Regarding Proposed Acquisition of Mylan (MYL)
April 22, 2015 8:33 AM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (NASDAQ: MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Tevas proposal for Mylan implies a total equity value of approximately $43 billion and an... More
